Prognostic Implications of EGFR and HER-2 Alteration Assessed by Immunohistochemistry and Silver in Situ Hybridization in Gastric Cancer Patients Following Curative Resection

Overview

Journal Gastric Cancer

Specialties Gastroenterology
Oncology

Date 2013 Aug 20

PMID 23955257

Citations 20

Authors

Ho Suk Oh

Dae-Woon Eom

Gil Hyun Kang

Yong Chel Ahn

Sang Jin Lee

Ji-Hoon Kim

Hyuk Jai Jang

Eun Jung Kim

Kwang Hoon Oh

Heui June Ahn

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to use immunohistochemistry (IHC) and silver in situ hybridization (SISH) to evaluate alterations in EGFR and HER2 in gastric cancer in order to determine the relationship with prognosis in gastric cancer patients following curative resection.

Patients And Methods: In this study, we analyzed EGFR and HER-2 status by IHC and SISH in 254 stage I-III gastric cancer patients who underwent curative surgery.

Results: Thirteen cases (2.48 %) showed EGFR alteration by IHC or SISH. EGFR alteration was associated with older age (P = 0.021), intestinal type (P = 0.040) and higher stage disease (P < 0.001). The patients with operable state gastric cancer who had EGFR alteration had an unfavorable prognosis, and multivariate analysis confirmed that EGFR alteration was an independent unfavorable prognostic factor. Twenty-seven cases (10.6 %) showed HER-2 alteration by IHC or SISH. HER-2 alteration was associated with older age (P = 0.006), well or moderately differentiated histology (P < 0.001) and intestinal type (P = 0.002).

Conclusion: HER-2 alteration is not an independent prognostic factor for curatively resectable gastric cancer. We observed EGFR alteration in a subset of cases with operable state gastric cancer and determined that it was associated with an unfavorable prognosis.

Citing Articles

Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis.

Tsujio G, Maruo K, Yamamoto Y, Sera T, Sugimoto A, Kasashima H BMC Cancer. 2022; 22(1):598.

PMID: 35650563 PMC: 9161565. DOI: 10.1186/s12885-022-09681-3.

Expression of HER2/c-erbB-2, EGFR Protein in Gastric Carcinoma and its Clinical Significance.

Cheng G, Mei Y, Pan X, Liu M, Wu S Open Life Sci. 2021; 14:119-125.

PMID: 33817143 PMC: 7874756. DOI: 10.1515/biol-2019-0013.

The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer.

Li G, Jia X, Zhao Q, Zhang H, Yang P, Xu L Medicine (Baltimore). 2020; 99(21):e20460.

PMID: 32481349 PMC: 7249938. DOI: 10.1097/MD.0000000000020460.

Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II/III Gastric Cancer.

Kano K, Yamada T, Yamamoto K, Komori K, Watanabe H, Hara K Ann Surg Oncol. 2020; 27(11):4235-4247.

PMID: 32424582 DOI: 10.1245/s10434-020-08616-1.

Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/β-Catenin Pathway.

Wang X, Lu B, Dai C, Fu Y, Hao K, Zhao B Front Oncol. 2020; 10:46.

PMID: 32117718 PMC: 7008851. DOI: 10.3389/fonc.2020.00046.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Kim M, Jung E, Lee H, Lee H, Jeon Y, Yang H . Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007; 38(9):1386-93. DOI: 10.1016/j.humpath.2007.02.005. View

Baselga J, Arteaga C . Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23(11):2445-59. DOI: 10.1200/JCO.2005.11.890. View

Ito R, Nakayama H, Yoshida K, Matsumura S, Oda N, Yasui W . Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma. Virchows Arch. 2004; 444(4):324-31. DOI: 10.1007/s00428-004-0982-8. View

Mendelsohn J, Baselga J . Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21(14):2787-99. DOI: 10.1200/JCO.2003.01.504. View

Matsubara J, Hirashima Y, Yamada Y . [Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer]. Gan To Kagaku Ryoho. 2010; 37(8):1489-96. View

Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A . Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol. 1997; 151(3):761-8. PMC: 1857861. View

Tanner M, Hollmen M, Junttila T, Kapanen A, Tommola S, Soini Y . Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005; 16(2):273-8. DOI: 10.1093/annonc/mdi064. View

Sanz-Ortega J, Steinberg S, Moro E, Saez M, Lopez J, Sierra E . Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol. 2000; 15(2):455-62. DOI: 10.14670/HH-15.455. View

10.

Park Y, Hwang H, Park H, Ryu M, Chang H, Yook J . Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?. Hum Pathol. 2011; 43(3):413-22. DOI: 10.1016/j.humpath.2011.05.019. View

11.

Chang H, Jung K, Kim T, Kim W, Yang H, Lee K . A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer. Ann Oncol. 2002; 13(11):1779-85. DOI: 10.1093/annonc/mdf302. View

12.

Chong G, Cunningham D . Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol. 2005; 31(5):453-60. DOI: 10.1016/j.ejso.2005.02.026. View

13.

Park D, Yun J, Park J, Oh S, Kim H, Cho Y . HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006; 51(8):1371-9. DOI: 10.1007/s10620-005-9057-1. View

14.

Wagner A, Moehler M . Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol. 2009; 21(4):381-5. DOI: 10.1097/CCO.0b013e32832c42e0. View

15.

Kopp R, Rothbauer E, Ruge M, Arnholdt H, Spranger J, Muders M . Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res. 2003; 162:115-32. DOI: 10.1007/978-3-642-59349-9_10. View

16.

Galizia G, Lieto E, Orditura M, Castellano P, La Mura A, Imperatore V . Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007; 31(7):1458-68. DOI: 10.1007/s00268-007-9016-4. View

17.

Mathisen D, Kuo E, Hahn C, Moncure A, Wain J, Grillo H . Inhaled nitric oxide for adult respiratory distress syndrome after pulmonary resection. Ann Thorac Surg. 1999; 66(6):1894-902. DOI: 10.1016/s0003-4975(98)01167-9. View

18.

Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A . Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst. 2007; 99(8):601-7. DOI: 10.1093/jnci/djk131. View

19.

Park D, Lee H, Kim H, Yang H, Lee K, Choe K . Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005; 92(9):1099-102. DOI: 10.1002/bjs.4952. View

20.

Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P . Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 2003; 10(3):234-41. DOI: 10.1245/aso.2003.05.010. View